Remus Pharmaceuticals Limited Share Price & Stock Analysis

Remus Pharmaceuticals Limited (NSE: REMUS) is an Ahmedabad, Gujarat-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹941 Cr, it ranks #1,623 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 13 in Pharmaceutical Product Distribution. At ₹820.00 (as of 16 Nov 2026), the share price is 21.1% below its 52-week high of ₹1,039.00 and 41.4% above its 52-week low of ₹580.00. The share price is up 0.6% over one year and down 7.7% over three months.

Key Metrics

Current Price₹820.00
Market Cap₹941 Cr
NSE SymbolREMUS
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Distributors > Pharmaceutical Product Distribution
P/E Ratio26.1
Return on Equity13.78%
Return on Assets6.67%
52-Week Range₹580.00 – ₹1,039.00
1-Year Price Change+0.6%
3-Month Price Change-7.7%
Beta (1Y)0.54
Dividend Yield0.12%
HeadquartersAhmedabad, Gujarat
Websiteremuspharma.com

Shareholding and Delivery

Promoters held 70.95% of Remus Pharmaceuticals Limited's shares as of Sept 2026, against 70.91% in Sept 2025 (+0.04 percentage points).

About Remus Pharmaceuticals Limited

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels, ointments, suspensions, oral solutions and suspensions, sachets, and ophthalmic and other dosage forms. It also exports its products. Remus Pharmaceuticals Limited was incorporated in 2015 and is based in Ahmedabad, India.

Products and Services

1. Pharmaceutical-This segment engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Pharmaceutical-100%

Remus Pharmaceuticals Limited vs Peers — Pharmaceutical Product Distribution

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Entero Healthcare Solutions Limited₹8,733 Cr74.68.28%₹2,087 Cr+80.7%
Remus Pharmaceuticals Limited₹941 Cr26.113.78%—+0.6%
Health X Platform Limited (Sastasundar Ventures Ltd)₹871 Cr752.7-0.18%₹484 Cr-5.7%
Aptus Pharma Limited₹837 Cr156.8——+754.0%
Vasa Denticity Limited₹797 Cr76.56.68%₹87 Cr-21.4%
Bijoy Hans Ltd₹523 Cr———+128.4%
Speciality Medicines Limited₹149 Cr11.5———
Vijaypd Ceutical Limited₹136 Cr239.53%——
Royal Sense Limited₹39 Cr5.6——-71.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited is trading at ₹820.00, with a market capitalisation of ₹941 Cr.

Which sector does Remus Pharmaceuticals Limited belong to?

Remus Pharmaceuticals Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).

What are the key financial ratios of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited has a P/E of 26.1 and a return on equity of 13.78%.

What is the stock symbol of Remus Pharmaceuticals Limited?

Remus Pharmaceuticals Limited is listed on the NSE under the symbol REMUS.

How has Remus Pharmaceuticals Limited's share price moved over the past year?

Remus Pharmaceuticals Limited's share price is up 0.6% over one year and down 7.7% over three months. Its 52-week range is ₹580.00 to ₹1,039.00.

What is the promoter holding in Remus Pharmaceuticals Limited?

Promoters held 70.95% of Remus Pharmaceuticals Limited's shares as of Sept 2026, against 70.91% in Sept 2025 (+0.04 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.